ArticleFrontiers in pharmacology2026
Exploring the analgesic effect of artificial dura mater as a carrier for local hydromorphone delivery in posterior lumbar interbody fusion: a randomized controlled trial.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Carrier-based local hydromorphone delivery using absorbable materials represents an innovative strategy; however, comparative studies on various carriers remain scarce. This study aims to evaluate and compare the clinical efficacy of artificial dura mater versus gelatin sponge as carriers for hydromorphone in patients undergoing posterior lumbar interbody fusion (PLIF). Methods: This single-center, prospective, randomized controlled trial was conducted at Ganzhou People's Hospital, with planned enrollment of patients scheduled for single-level PLIF surgery. Participants were randomly assigned to either the gelatin sponge group (Group G) or the artificial dura mater group (Group A). At the conclusion of the surgery, the carrier material was soaked with 0.4 mg of hydromorphone hydrochloride and subsequently placed evenly onto the dural surface. The primary outcome was overall analgesic efficacy during movement within 72 h postoperatively. Secondary outcomes included the overall analgesic efficacy at rest within 72 h postoperatively, Visual Analog Scale (VAS) scores at rest and during movement at 24, 48, and 72 h postoperatively, patient satisfaction, hemodynamic parameters, adverse reactions, analgesic consumption, postoperative Quality of Recovery-15 (QoR-15) score, and Pittsburgh Sleep Quality Index (PSQI) score. Results: Between February 2025 and July 2025, Seventy-four patients were randomized, and 71 were included in the modified intention-to-treat (mITT) analysis (Group G: n = 35; Group A: n = 36). Group A showed a modest reduction in the area under the curve (AUC) of the time-VAS curve during movement from PACU to 72 h (Median difference, -24; 95%CI, -36 to 0; Conclusion: Artificial dura mater-based local hydromorphone delivery may alleviate movement-evoked pain at 72 h after PLIF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.